Financial Projections - The estimated net profit for 2024 is projected to be between 190 million and 270 million CNY, a decrease of 68.65% to 77.94% compared to the previous year's net profit of 861.30 million CNY [3]. - The estimated net profit after deducting non-recurring losses is projected to be between 205 million and 290 million CNY, a decrease of 59.84% to 71.61% compared to the previous year's figure of 722.05 million CNY [3]. - The impact of non-recurring gains and losses on net profit is estimated to be between -20 million and -15 million CNY, compared to 139.25 million CNY in the previous year [4]. Revenue Decline Factors - The decline in revenue is attributed to market competition and inventory reduction, along with increased fixed asset depreciation and asset impairment [4]. Communication with Accounting Firm - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant discrepancies [3].
康泰生物(300601) - 2024 Q4 - 年度业绩预告